Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Up 0.8% in July: Crecon
September 9, 2022
- Lagevrio’s Normal Distribution to Start from Sept. 16: MSD
September 9, 2022
- Samsca Generics Get Additional Indication for Heart Failure, AG Too
September 8, 2022
- AnGes Calls off Japan Development of Collategene for Additional Indication
September 8, 2022
- AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
- Promotions via In-Hospital Seminars, Webinars Record Two-Digit Rise YOY in July: Intage
September 7, 2022
- Sysmex Files Gene Profiling Test as CDx for Taiho’s Futibatinib
September 7, 2022
- Opdivo Best-Selling Drug in Japan for 8 Months on End: Encise
September 7, 2022
- Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
- Tatsumi Kagaku Likely to Halt Shipments of 46 Products after Administrative Penalty
September 6, 2022
- Moderna to File BA.4/5-Targeting Booster Jab in Japan
September 6, 2022
- Teijin Gets Approval for 14-Day Version of Osteoporosis Med Ostabalo
September 6, 2022
- Leo Pharma Japan Names Finance Head Kook Hyun Son as Interim Chief
September 2, 2022
- Nitrosamine Impurity Detected in Sitagliptin, Shipments in Japan to Continue with FDA-Set Limit: MSD/Ono
September 2, 2022
- CureApp’s Hypertension Therapeutic App Rolls Out with Insurance Coverage
September 2, 2022
- AstraZeneca Japan Sets Up New Biz Unit for Vaccines and Immune Therapies
September 2, 2022
- Daiichi Sankyo Begins PIII Primary Dose Study for mRNA COVID Jab
September 2, 2022
- Pfizer Discussing Filing of BA.5-Based Vaccine with Japanese Authorities
September 1, 2022
- Servier to Bolster Japan Business with Focus on Oncology: President Laureau
September 1, 2022
- Pfizer Japan to Curb Shipments and Recall Amoxapine over Carcinogen Risks
September 1, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…